振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查

证券之星07-03

证券之星消息，振东制药(300158)07月02日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘你好，请问振东制药创新药二联活菌胶囊生产线是否已建设完成？中药创新药星篓承气颗粒临床进展是否一切顺利？

振东制药回复：尊敬的投资者您好！为加快商业化进程，公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2648667126?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-03 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648667126","market":"hk","top_or_hot":-1,"title":"振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300158\">振东制药</a>(300158)07月02日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘你好，请问振东制药创新药二联活菌胶囊生产线是否已建设完成？中药创新药星篓承气颗粒临床进展是否一切顺利？</p><p>振东制药回复：尊敬的投资者您好！ 为加快商业化进程，公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-03 20:51 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026070300043005.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，振东制药(300158)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问振东制药创新药二联活菌胶囊生产线是否已建设完成？中药创新药星篓承气颗粒临床进展是否一切顺利？振东制药回复：尊敬的投资者您好！ 为加快商业化进程，公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026070300043005.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://stock.stockstar.com/RB2026070300043005.shtml","article_id":"2648667126","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648667126","pubTimestamp":1783083099,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，振东制药(300158)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问振东制药创新药二联活菌胶囊生产线是否已建设完成？中药创新药星篓承气颗粒临床进展是否一切顺利？振东制药回复：尊敬的投资者您好！ 为加快商业化进程，公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300158":"振东制药","BK0060":"抗癌","BK0239":"医药制造","BK0186":"小盘成长"},"translate_title":"Zhendong Pharmaceutical: Longchuangji Pharmaceutical, in which the company has a stake, has completed the construction of the production line of Lactobacillus grazieri double live bacteria capsules and passed the GMP compliance inspection","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300158":1.5},"content_text":"证券之星消息，振东制药(300158)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问振东制药创新药二联活菌胶囊生产线是否已建设完成？中药创新药星篓承气颗粒临床进展是否一切顺利？振东制药回复：尊敬的投资者您好！ 为加快商业化进程，公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648667126","isCrawlerRequest":true}